Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.

Mantle cell lymphoma (MCL), an aggressive B-cell malignancy accounting for 6% of non-Hodgkin lymphomas, remains incurable with standard therapy. Despite the approval of bortezomib,1 temsirolimus,2 lenalidomide,3 ibrutinib4 and acalabrutinib,5 patients with relapsed, refractory MCL have a survival of 2 years